Stockwinners Market Radar for March 14, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:50 EDT Graphite Bio trading halted, news pending

18:34 EDT Movano's Evie Ring pulse oximeter exceeds FDA accuracy guidelines - Movano Health has completed another hypoxia trial with the University of California, San Francisco yielding new blood oxygen saturation data, confirming the accuracy of its Evie Ring pulse oximeter exceeds the FDA guidelines. The Evie Ring entered commercial production in late 2023 as a consumer wellness device. This latest UCSF study, completed in Q1, used the production model ring, which reflected several design improvements from the pre-commercial model used in the earlier study and will be submitted to FDA and sold under the brand name Evie Med. During the second trial, the four Evie Rings achieved a root mean square error average of 2.46%, which was once again well below the FDA guidance of 3.5% for SpO2. Additionally, the Evie Ring's accuracy exceeded that of the two commercially available, hospital-grade reference pulse oximeters in the study. The company plans to address the outstanding FDA comments from August 2023 for the Evie Med Ring in April 2024 and present the corroborating data from Q1 clinical study. Movano Health expects to receive a decision regarding its 510(k) clearance in July.

18:14 EDT Embracer Group to sell select assets from Saber Interactive for $247M - Embracer Group has entered into an agreement to divest selected assets, from the operative group Saber Interactive for a purchase price of $247M, including assumed earnout liabilities of $44M but before any additional consideration. Through this divestment, Embracer ceases all operations in Russia, while immediately improving cash flow, reducing capex, net debt and future liabilities. The buyer is Beacon Interactive, a company controlled by Saber Interactive co-founder Matthew Karch. "I am pleased that we have found a win-win solution for Embracer and the parts of Saber that now will leave us. This transaction puts both companies in a stronger position to thrive going forward. Embracer is now able to discontinue all operations in Russia, according to a previous board decision, while safeguarding many developer jobs under new independent ownership. At the same time, we keep key companies, valuable IPs and future publishing rights. Cash flow is immediately improved, and we remain committed to reducing net debt. The transaction yields additional headroom to amortize debt in accordance with existing bank agreements and will improve financial flexibility. This is the first transaction of the previously mentioned structured processes and marks a small but important step in our journey to transform Embracer into the future for the benefit of all employees, gamers, and shareholders," says Lars Wingefors, co-founder and Group CEO of Embracer. Furthermore, Embracer will be entitled to an additional consideration of up to $94M if the Buyer resells the assets for a higher consideration subject to certain conditions and time periods. The divested assets include 38 ongoing game development projects, amounting to a book value of around SEK2.3B. The divested assets also include certain proprietary engine technology and game tools relating to the divested companies.

17:41 EDT Adobe sees Q2 tax rate 18.5% - Says not updating FY24 targets on this call. Sees Q2 digital media annual recurring revenue $440M. Says experienced particular strength in enterprise segment. Says pleased with strong Q1. Says FY24 is off to strong start. Says focused on expanding access to users. Says creative cloud pricing and enterprise monetizing in line with expectations. Says still in user acquisition mode. Comments and guidance taken from Q1 earnings conference call.

17:21 EDT Wheaton Precious Metals sees 2029-2033 average production over 850K gold eq. oz.

17:13 EDT Wheaton Precious Metals increases dividend 0.5c to 15.5c pe share - Wheaton Precious Metals has declared its first quarterly cash dividend payment for 2024 of 15.5c per common share, an increase from the fourth quarterly cash dividend payment for 2023 of 15c per common share. The first quarterly cash dividend for 2024 will be paid to holders of record of Wheaton common shares as of the close of business on April 3, and will be distributed on or about April 15, 2024. The ex-dividend trading date is April 2.

16:51 EDT Employers Holdings chair Michael McSally to step down, Jeanne Mockard to succeed - Employers Holdings announced that the chair of its board of directors, Michael McSally, will be stepping down as board chair. The board of directors has unanimously elected board member Jeanne Mockard as the incoming board chair, effective March 20.

16:45 EDT Madrigal Pharmaceuticals trading resumes

16:38 EDT International Game's IGT PlayDigital content now live in Rhode Island - International Game's IGT PlayDigital iGaming content library is now available in Rhode Island via the Bally Casino Rhode Island app and on BallyCasino.com. This content deployment makes IGT PlayDigital one of only two suppliers to offer content in all seven U.S. online gaming jurisdictions.

16:36 EDT Colgate-Palmolive raises quarterly dividend to 50c per share from 48c - The Board of Directors of Colgate-Palmolive Company increased the quarterly common stock cash dividend to 50c per share, up from 48c per share. The increase will be effective in the second quarter, 2024. The Board declared that the second quarter dividend is to be paid on May 15, 2024 to shareholders of record as of April 22, 2024. On an annualized basis, the new dividend rate is $2.00 versus $1.92 per share previously. The Company has paid uninterrupted dividends on its common stock since 1895.

16:35 EDT FDA clears Intuitive Surgical's 'fifth-generation robotic' da Vinci 5 - Intuitive announced that the U.S. Food and Drug Administration FDA provided 510k clearance for da Vinci 5, the company's next-generation multiport robotic system."We are pleased to receive FDA clearance for our fifth-generation robotic system, da Vinci 5," said Gary Guthart, CEO. "Intuitive is committed to meaningful improvements in surgery that enable better patient outcomes, enhance the patient and care team experiences, and ultimately lower the total cost of care. After more than a decade of careful research, design, development, and testing, we believe da Vinci 5 will deliver on these goals and help drive the future of robotic-assisted surgery." Da Vinci 5 builds on Intuitive's da Vinci Xi's highly functional design, which surgeons and care teams around the world have used in more than 7 million procedures to date.

16:30 EDT Sprinklr, Tech Mahindra partner over AI-first customer experience platform - Sprinklr announced a strategic partnership with a leading provider of digital transformation, consulting, and business re-engineering services and solutions, Tech Mahindra. Tech Mahindra and Sprinklr together will implement an AI-first customer experience management platform that delivers unified services across touchpoints and focus on go-to-market strategies. After collaborating on joint implementations in Europe, the two organizations have decided to formalize and expand their relationship globally. The partnership will empower enterprises to better manage customer journeys across customer service, social media, sales, and marketing.

16:28 EDT BeiGene receives FDA approval for Tevimbra - BeiGene announced that the U.S. Food and Drug Administration has approved TEVIMBRA as monotherapy for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor. TEVIMBRA will be available in the U.S. in the second half of 2024. "Today's FDA approval of TEVIMBRA for patients with ESCC who have previously received chemotherapy, along with its ongoing review of our BLA for first-line ESCC patients, represents a significant step in our commitment to bringing this therapy to more patients around the world," said Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeiGene. "As BeiGene's first drug candidate produced through our immuno-oncology program and second approved medicine in the U.S., TEVIMBRA is poised to be a critical pillar of our solid tumor development program, which spans more than 17 registration-enabling clinical trials in more than 30 countries across regions globally."

16:24 EDT Nuvation Bio doses first patient in Phase 1/2 study of NUV-1511 - Nuvation Bio announced that the first patient has been dosed in a Phase 1/2 study of NUV-1511, the Company's first DDC to enter the clinic. "Dosing the first patient with NUV-1511 marks a significant milestone for our proprietary DDC platform, from which we are developing potent oncology-focused chimeric small molecules designed to selectively deliver anti-cancer therapeutics to cancer cells, while mitigating effects on healthy non-target tissues," said David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio. "DDCs are the core technology upon which the Company was founded and we are excited to bring our first DDC clinical candidate to patients." The dose escalation portion of the study employs a flexible design that allows for the potential to explore two dosing schedules for NUV-1511 with the goal of establishing the recommended Phase 2 dose. The study will initially evaluate safety and tolerability, pharmacokinetic profile, and assess for signs of clinical activity in patients with advanced solid tumors who previously received and progressed on or after treatment with Enhertu and/or Trodelvy per approved U.S. Food and Drug Administration (FDA) labeling, human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer, metastatic castration-resistant prostate cancer (mCRPC), advanced pancreatic cancer, and platinum-resistant ovarian cancer (PROC).

16:21 EDT Larimar Therapeutics provides update on nomlabofusp development - In March, the first patient in the OLE study evaluating daily subcutaneous injections of 25 mg of nomlabofusp self-administered or administered by a caregiver was dosed. Participants who completed treatment in the Phase 2 dose exploration trial, or who previously completed a prior clinical trial of nomlabofusp, are potentially eligible to screen for the OLE study. The OLE study will evaluate the safety and tolerability, pharmacokinetics, and frataxin levels in peripheral tissues as well as other exploratory pharmacodynamic markers following long-term subcutaneous administration of nomlabofusp. Clinical assessments collected during the trial will be compared to data from a matched control arm derived from participants in the Friedreich's Ataxia Clinical Outcome Measures Study, or FACOMS, database. Interim data is expected in Q4 2024. To potentially escalate dose in the OLE study, data from the 50 mg cohort of the Phase 2 study, as well as available data from the 25 mg dose in the OLE study will be submitted for FDA review due to continued partial clinical hold. Ben-Maimon continued, "On the regulatory front, we are continuing discussions with the FDA on the potential use of frataxin as a novel surrogate endpoint to support accelerated approval. We are also beginning to plan for a global double-blind placebo-controlled confirmatory study expected to be initiated prior to a potential BLA submission. The BLA submission is targeted for the second half of 2025. We believe our clinical datasets supporting nomlabofusp's differentiated mechanism of action, coupled with our strengthened balance sheet and expected runway into 2026, strongly position us for execution of our upcoming pivotal milestones designed to help address the urgent unmet needs of the FA community."

16:18 EDT CS Disco board approves $20M share repurchase authorization - CS Disco announced that its Board of Directors has approved a share repurchase program authorizing the company to repurchase up to $20M of its outstanding shares of common stock. "We believe DISCO's shares are undervalued and this repurchase program is a prudent use of capital that underscores our commitment to enhancing stockholder value," said Scott Hill, Chief Executive Officer of DISCO.

16:11 EDT Intensity Therapeutics says cash sufficient to fund operations through 1Q25 - As of December 31, 2023, cash, cash equivalents and marketable debt securities totaled $14.8M, which the company expects will be sufficient to fund operations through the end of the first quarter in 2025. "We had a pivotal year in 2023 culminating with the receipt of an FDA 'Study May Proceed' letter to enter into Phase 3 clinical trials for our lead drug candidate, INT230-6 for metastatic soft tissue sarcoma," said Lewis Bender, Founder, President and CEO. "Our selection this year by the review committees at ASCO, CTOS and SABCS, including oral podium presentations, validated our science and indicated interest by oncologists in our results. We are on track to initiate our Phase 3 sarcoma study in mid-2024. Following our IPO, our cash position remains strong, and we believe we have sufficient runway to meet near term milestones."

16:08 EDT Trinity Capital increases dividend 2.0% to 51c per share - Trinity Capital declared a cash dividend of 51c per share with respect to the quarter ending March 31, 2024. This dividend represents an increase of 2.0% over the regular dividend declared in the prior quarter. The dividend will be paid on April 15 to those shareholders on record March 28.

16:07 EDT Kennametal says Sanjay Chowbey to succeed Christopher Rossi as CEO - Kennametal announced that Sanjay Chowbey, currently Vice President, Kennametal and President, Metal Cutting Segment, will succeed Christopher Rossi as President & CEO. Rossi has decided to retire from the company after nearly seven years as CEO, effective May 31. Chowbey was unanimously appointed by the Board of Directors as Rossi's successor, effective June 1. Rossi will continue to serve on the company's Board of Directors until his retirement, at which time Chowbey will join the Board. Rossi and Chowbey will work together to ensure a seamless transition. Chowbey joined Kennametal in 2021 as President of the Metal Cutting segment. Under his leadership the business has grown its customer base, consistently delivered sales growth, expanded its operating margins, launched more than 20 new products and improved employee engagement. The Company has launched a search for Chowbey's Metal Cutting successor, considering both internal and external candidates. Chowbey will also continue in his current role during this transition period until he officially steps into the CEO role.

15:56 EDT Geron reports FDA advisors vote in favor of benefit/risk of imetelstat - Geron announced that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee, or ODAC, voted 12 to 2 in favor of the clinical benefit/risk profile of imetelstat for the treatment of transfusion-dependent anemia in adult patients with low-to-intermediate-1 risk myelodysplastic syndromes who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents. "We are pleased with the Committee's decision to recognize the positive clinical benefit/risk profile of imetelstat for the treatment of transfusion-dependent anemia in adult patients with lower-risk MDS. There are few treatment options and significant unmet medical need remains for these patients, particularly among those with difficult-to-treat subtypes of this blood cancer. We believe that imetelstat has the potential to be an important new medicine for patients and look forward to continuing our collaboration with the FDA as they complete their review of our New Drug Application," said Faye Feller, M.D., Geron's Executive Vice President, Chief Medical Officer. The FDA assigned a Prescription Drug User Fee Act, or PDUFA, target action date of June 16 for Geron's New Drug Application for imetelstat for the treatment of TD anemia in adult patients with low- to intermediate-1 risk myelodysplastic syndromes, who have failed to respond, or have lost response to, or are ineligible for ESAs. "The ODAC provides the FDA with independent opinions and recommendations from outside medical experts, patients and caregivers, though the recommendations are not binding. Geron plans to commercially launch imetelstat in the U.S. upon potential FDA approval," the company stated.

15:29 EDT Madrigal Pharmaceuticals trading halted, news pending

14:13 EDT Genius Group completes FatBrain AI merger - Genius Group (GNS) and FatBrain AI (LZGI), an AI SaaS and Solutions company, announced completion of their merger to form "an AI-powered Education and Acceleration group to power Sovereign AI ecosystems of tomorrow for entrepreneurs, enterprises, governments and students through AI education and enablement." Following NYSE approval, Genius Group completed the merger, acquiring FatBrain AI in an all-stock transaction. Under the terms of the agreement, Genius Group has acquired the AI software assets, customer relationships and specific operations of FatBrain AI, with an anticipated increase of approximately 150% in the company's 2023 pro forma revenue guidance to an estimated $76M-$80M, and an anticipated increase of $4M in pro forma net profit guidance to $7M-$9M. Roger Hamilton, CEO of Genius Group said: "The demand for AI and entrepreneurial skills continues to grow. Countries and cities around the world are seeing these skills as increasingly vital to be competitive in the age of AI. The desire for Sovereign AI institutions where countries, cities and companies can own their own data and build their own AI platform calls for localized education platforms. While 'Smart Cities' have been defined by the use of smart technology, our 'Genius City' model calls for upskilled humans alongside smart technologies and puts personalized education and peer intelligence at the heart of driving growth."

14:04 EDT BeiGene gets approval for Tevimbra BLA - The FDA granted approval for the biologics license application, or BLA, submitted by BeiGene U.S.A. for Tevimbra injection, for intravenous use, according to a letter posted to the agency's website. Reference Link

13:31 EDT GE HealthCare renews collaboration with Hartford HealthCare - GE HealthCare and Connecticut-based Hartford HealthCare announced that they have renewed a seven-year collaboration that began in 2016 to now extend through 2030. "Hartford HealthCare will upgrade its imaging technology using a phased approach to the acquisition, deployment and redeployment of essential equipment like CT, PET/CT, MRI, X-ray, nuclear medicine, mammography, ultrasound and OEC 3D surgical imaging C-arm, keeping Hartford HealthCare's imaging technologies current with the latest advancements in software, artificial intelligence and future innovations. The collaboration will increase patients' access to GE HealthCare's most current imaging technology, and may provide shorter scan times, reduced waiting times for care, and enable clinicians to have greater accuracy in diagnostic assessments. The agreement also includes GE HealthCare patient monitoring, anesthesia, maternal infant care and diagnostic cardiology technologies," the company stated.

13:02 EDT BAE Systems awarded $86M contract by U.S. Navy - The U.S. Navy has awarded BAE Systems a contract worth approximately $86M to continue supporting its Mobile Deployable Command, Control, Communications, Computers, Combat Systems, Intelligence, Surveillance, and Reconnaissance programs. The five-year contract from the U.S. Naval Air Systems Command's Naval Air Warfare Center Aircraft Division Webster Outlying Field Special Communications Mission Solutions Division will involve the company providing engineering and technical services for new and legacy MDC5ISR systems and platforms.

12:20 EDT FutureFuel trading resumes

12:00 EDT Dick's Sporting rises 13.3% - Dick's Sporting is up 13.3%, or $24.98 to $212.74.

12:00 EDT Vaalco Energy rises 17.5% - Vaalco Energy is up 17.5%, or 78c to $5.24.

12:00 EDT Under Armour falls -12.7% - Under Armour is down -12.7%, or -$1.03 to $7.07.

11:45 EDT EchoStar says all 2023 FCC 5G commitments complete after nationwide drive test - EchoStar Corporation filed a letter with the Federal Communications Commission certifying that its nationwide 5G network provides download speeds of 35 Mbps or greater to over 70 %of the U.S. population, the company announced. This certification follows the successful completion of a nationwide drive test, fulfilling the final element of EchoStar's 2023 deployment commitments to the FCC. The drive test, conducted using an FCC-approved methodology and overseen by an independent monitor, is the third and final component of EchoStar's 2023 Nationwide 5G Deployment Commitment to the FCC, the company stated. "Today marks another milestone as we continue to build the world's first commercial-grade Open RAN 5G network and provide Americans with more options for wireless service. This drive test confirms the Boost Wireless Network is delivering high-quality service to our customers. It's a major achievement for our team who built our Open RAN network in record time," said John Swieringa, president of technology and COO, EchoStar.

11:27 EDT Minim Inc trading resumes

11:19 EDT Grom Social Enterprises enters Letter of Intent to acquire Arctic7 - Arctic7, which provides a suite of full game and co-development services together with own intellectual property development within gaming, and virtual production services for the movie and TV industry, has announced it has agreed to be acquired by Grom Social Enterprises. Grom CEO Darren Marks said: "Grom welcomes the opportunity to bring Arctic7 into the Grom portfolio to further fuel Arctic7's vision of offering both gaming and virtual production capabilities, while together, we explore integrating Arctic7's expertise into our expanding entertainment ecosystem. Content collaboration, cross-promotional opportunities, product licensing, brand partnerships, merchandising, interactive experiences, educational gaming initiatives, and much more are at the heart of this partnership." "Upon completion of the acquisition, Arctic7 will operate as a division within Grom and will continue to execute against its current strategy of delivering exciting and engaging experiences for players and partners. In the coming weeks and months, Grom and Arctic7 intend to explore partnership opportunities and titles presented by the Grom acquisition," Arctic7 stated.

11:06 EDT Fed issues enforcement action against JPMorgan Chase, issues $98M in fines - The Federal Reserve Board issued an enforcement action against JPMorgan Chase and fined the firm approximately $98.2M for an inadequate program to monitor firm and client trading activities for market misconduct. The Board's action requires JPMorgan Chase to review and take corrective action to address the firm's inadequate monitoring practices, which occurred between 2014 and 2023. The Board's action was taken in coordination with the Office of the Comptroller of the Currency. The penalties announced by the Board and the Office of the Comptroller of the Currency total approximately $348.2M, the Fed stated. Reference Link

11:01 EDT Jin Medical International Ltd trading halted, volatility trading pause

10:25 EDT Dollar General doesn't see repurchasing common stock this year - Kelly Dilts, Chief Financial Officer of Dollar General, stated on the company's earnings call, according to a transcript: "Finally, to support reducing our debt leverage ratio, and maintaining our current investment-grade credit ratings, we do not plan to repurchase common stock this year under our board authorized repurchase program, although as I mentioned, share repurchases remain a part of our future capital allocation strategy. Although our leverage ratio is currently above our target of approximately three times adjusted debt-to-adjusted EBITDAR, we are focused on improving our debt metrics in support of our commitment to our current investment-grade credit ratings which as a reminder, our triple B and BAA too. Cash generation is always important and we are focused on further improving cash flow as we move through 2024. We believe these actions, which are aligned with our capital allocation priorities, will continue to strengthen our overall financial position for 2024 and beyond."

10:15 EDT FutureFuel trading halted, news pending

10:09 EDT AASLD says Madrigal Pharmaceuticals' MASH therapy resmetirom approved - The American Association for the Study of Liver Diseases, or AASLD, said in a press release that it is "pleased to see the recent support from the U.S. Food and Drug Administration for Madrigal Pharmaceuticals' innovative therapy, resmetirom, for the treatment of at-risk Metabolic dysfunction-Associated Steatohepatitis," or MASH. "This landmark approval marks a significant advancement in the field of hepatology, as resmetirom becomes the first FDA-approved therapy specifically indicated for MASH, offering new hope for patients and clinicians alike. FDA's decision to approve resmetirom gives clinicians a valuable tool in their arsenal against MASH and underscores the importance of continued research and innovation in liver disease management," the AASLD stated. Reference Link

10:01 EDT Altria Group says 2024 outlook excludes income from AB InBev sale - Altria Group (MO) said, "The 2024 full-year adjusted diluted EPS guidance range excludes estimated net income of approximately $0.2 billion (or $0.12 per share) that we expect to record in the first quarter of 2024 for the partial sale of our investment in ABI (BUD). This estimated net income is subject to certain adjustments, including any exercise of the underwriters' option to purchase additional shares, adjustments related to the conversion from international financial reporting standards to U.S. generally accepted accounting principles and adjustments required under the equity method of accounting. Additionally, the guidance excludes an estimated per share gain of $1.17 related to the sale of the IQOS Tobacco Heating System commercialization rights that we expect to record in the second quarter of 2024."

10:01 EDT Altria raises buyback program by $2.4B in connection with AB InBev share sale - Altria Group (MO) announced that it has agreed to sell 35M shares of Anheuser-Busch InBev (BUD) through a global secondary offering comprised of a public offering of ABI ordinary shares represented by American depositary shares, or ADS, in the United States, a public offering of ABI ordinary shares in the United States, a concurrent private placement of ABI ordinary shares in the European Economic Area and the United Kingdom and an offering of ABI ordinary shares, including ABI ordinary shares represented by ADSs, in other countries outside the United States, at a price of $61.50 per ADS, corresponding to EUR 56.17 per ABI ordinary share. In addition, ABI will repurchase $200M of ordinary shares directly from Altria, concurrently with, and conditional on, completion of the offering. The aggregate amount of the offering and repurchase by ABI is approximately $2.4B. Altria has also granted the underwriters an option to purchase up to 5.25M additional ABI shares owned by Altria at the price per ADS paid by the underwriters in the offering, exercisable within the next 30 days. In connection with the pricing of the offering, Altria announces a $2.4B increase to its existing $1B share repurchase program. Its board has authorized the expanded program, which the company expects to complete by December 31, 2024. As part of the expanded share repurchase program, Altria expects to enter into an estimated $2.4B accelerated share repurchase, or ASR, program. It expects cash savings from the elimination of future dividend payments on the repurchased shares. "These opportunistic capital allocation decisions reflect our ongoing confidence in Altria's future and the significant value offered in our shares today. We have a longstanding history of returning cash to our shareholders, and today's announcement reflects our continued desire to create long-term shareholder value," said Billy Gifford, Altria's Chief Executive Officer.

10:00 EDT SentinelOne falls -10.5% - SentinelOne is down -10.5%, or -$2.93 to $25.01.

10:00 EDT Dick's Sporting rises 16.6% - Dick's Sporting is up 16.6%, or $31.24 to $219.00.

10:00 EDT Lithium Americas rises 24.2% - Lithium Americas is up 24.2%, or $1.39 to $7.12.

09:55 EDT Grifols sees addressing 2025 maturities 'efficiently' in first half of 2024 - Grifols said in a statement: "The rating review of Grifols by S&P and Fitch, which resulted in ratings of B and B+ respectively, down from the previous levels of B+ and BB- respectively, comes in light of the 2025 maturities. Rating agencies typically adopt a conservative stance without considering the current status of the efforts and advancements that Grifols is making to address such debt. Grifols continues to conduct business as usual and remain fully committed to implementing our plan to reduce leverage through accelerated EBITDA improvement and the proceeds from the USD 1.8bn Shanghai RAAS 20% sale. Such disposal execution continues to follow already-stated timings and is expected to close in the H1 of 2024.We expect to address our 2025 maturities efficiently in the first half of 2024, considering the SRAAS disposal proceeds and other available options. Executing these commitments will help Grifols achieve leverage levels that should serve as the basis for an improvement on the credit rating agencies' scorecards."

09:47 EDT Dick's Sporting rises 15.5% - Dick's Sporting is up 15.5%, or $29.07 to $216.83.

09:47 EDT Lithium Americas rises 24.6% - Lithium Americas is up 24.6%, or $1.41 to $7.14.

09:47 EDT Aspen Aerogels falls -8.9% - Aspen Aerogels is down -8.9%, or -$1.59 to $16.30.

09:46 EDT Solowin Holdings Ltd trading resumes

09:40 EDT Immuneering Corp trading resumes

09:38 EDT Nuvectis Pharma Inc trading halted, volatility trading pause

09:38 EDT H.I.G. Capital to acquire Thermal Commercial Vehcles Division from Valeo - H.I.G. Capital announced that one of its affiliates has signed a definitive agreement to carve out the Thermal Commercial Vehicles division from Valeo. The Company will operate under the name "Spheros" following closing. The transaction is expected to close this year and is subject to customary regulatory approvals. Headquartered in Germany, the Company is the leading global developer and manufacturer of thermal management solutions for a wide range of passenger buses and coaches, as well as refrigerated transportation fleets. The Company offers a comprehensive product portfolio, including air conditioning systems, heaters, coolant pumps, and other related hardware.

09:36 EDT Solowin Holdings Ltd trading halted, volatility trading pause

09:35 EDT BK Technologies Corp trading resumes

09:33 EDT Katapult Holdings trading halted, volatility trading pause

09:32 EDT Hallador Energy trading halted, volatility trading pause

09:31 EDT Mace Security, U.S. LawShield sign evergreen contract for training - Mace Security International and U.S. LawShield announced signing an evergreen contract to provide training for up to 26,000 employees of a nationwide service company. The training and Mace products are expected to produce revenues to Mace estimated at $300,000 over the course of the agreement. Under the agreement, Mace will provide the service company with Mace self-defense products, and U.S. LawShield will offer each employee training on a variety of subjects, including the following: how chemical irritants work; situational awareness techniques; and legal considerations.

09:29 EDT Lexaria Bioscience appoints Nelson Cabatuan as CFO - Lexaria Bioscience announces the appointment of Nelson Cabatuan, CPA, as CFO, effective immediately. As a member of the executive leadership team, Mr. Cabatuan will lead the Company's financial operations. Cabatuan has over 15 years of corporate finance and operations experience within the life sciences industry, most recently serving as SVP Finance and Operations at Rain Oncology, Inc., a late-stage precision oncology biotech company.

09:28 EDT Better Therapeutics trading halted, news pending

09:25 EDT Eventbrite announces $100M share repurchase pact - Eventbrite announced its Board of Directors has authorized the repurchase of up to $100M of outstanding Class A common stock. Under the program, Eventbrite may purchase shares of Class A common stock through open market purchases, block trades, privately negotiated transactions, accelerated share repurchase transactions, and/or pursuant to Rule 10b5-1 plans, in compliance with applicable securities laws and other legal requirements. The volume and timing of any repurchases will be subject to general market conditions, as well as Eventbrite's management of capital, general business conditions, other investment opportunities, and other factors. The repurchase program does not obligate Eventbrite to repurchase any specific number of shares, has no time limit, and may be modified, suspended, or discontinued at any time at the company's discretion.

09:24 EDT Bio-Path receives noncompliance letter from Nasdaq - In a regulatory filing, Bio-Path Holdings announced that it received a deficiency letter from the Listing Qualifications Department of Nasdaq notifying the company that it is not in compliance with the minimum stockholders' equity requirement of at least $2.5M for continued inclusion on Nasdaq pursuant to Nasdaq Listing Rule 5550. The letter has no effect on the listing of the company's common stock at this time, and the company's common stock will continue to trade on Nasdaq.

09:21 EDT Solowin Holdings announces expansion into Private Wealth Management business - SOLOWIN HOLDINGS announced its strategic expansion into the Private Wealth Management business under its newly formed Hong Kong subsidiary, Solomon Private Wealth Limited. The Company expects to serve a broad range of high-net-worth individuals, family offices, and trusts, by offering wealth management services and solutions that span traditional and virtual asset classes. To support this new expansion, the Company has opened a new office in the International Commerce Center in Hong Kong to house its growing team of professionals and to accelerate its diversification into this fast-growing business. This office also highlights SOLOWIN's commitment to building an integrated financial services infrastructure for next-generation investors.

09:20 EDT Mullen Automotive announces key sales hires - Mullen Automotive announced new key sales hires who have joined the Company in support of its commercial EV van and truck program. Tyler Jordan - Senior Director of Commercial Sales: Jordan has more than 13 years of experience driving profitability, growth, and process and program enhancements to service high-volume, multi-million-dollar accounts, leveraging strategic planning and data analysis. During the five years he spent with Merchants Fleet, Jordan was a key contributor to the growth of the Last Mile Delivery segment as both a strategic account executive and manager of the strategic accounts. In his role, Jordan collaborated with many different teams to create scalable, end-to-end processes that proved crucial in landing large strategic accounts such as Amazon, FedEx and UPS. Matt Nevious - Director of Commercial Sales/Strategic Accounts: Nevious played a pivotal role at Merchants Fleet in the growth and optimization of key accounts, particularly within Amazon Last Mile operations. He spearheaded the development of innovative programs tailored to the unique needs of clients like Amazon and FedEx. Jacob Frenning - Director of Commercial Sales Mid-Atlantic: Frenning has over 15 years of proven successful sales and leadership experience in automotive service, commercial sales and fleet management. In the past decade, Frenning has held positions in operations, sales, and management, and is passionate about applying these skills to deliver proven sales results. Frenning has strong contacts with fleets and is known for working hard to uncover new opportunities while strategically targeting key accounts and other growth engines.

09:18 EDT Sealsq launches SEALBOX - SEALSQ announced the launch of SEALBOX, its innovative solution for IoT device provisioning at the manufacturing level. SEALBOX is available now and it will be showcased at the upcoming CSA Member Meeting, taking place in Singapore from March 18 - 21. SEALBOX aims to address the current challenges in the IoT device provisioning process. This process of securely generating and provisioning device identity and data requires manufacturers to use a Public Key Infrastructure (PKI) to create and install a unique digital certificate. While it presents difficulties to both manufacturers and integrators, this process is crucial to guarantee device authentication and security. Providing each device with a distinct identity is also now enforced by prominent standards such as Matter, EV-charging, OPC-UA Industry 4.0, US Cyber Trust Mark, and the European Cyber Resilient Act.

09:16 EDT Edible Garden announces Pulp sauces available through KeHE distributors - Edible Garden announced at Natural Products EXPO WEST 2024 that KeHE Distributors will carry Edible Garden's new line of Pulp sustainable gourmet sauces and chili-based products.

09:13 EDT Broadcom delivers Bailly Ethernet switch to customers - Broadcom has delivered Bailly, the industry's first 51.2 terabits per sec co-packaged optics Ethernet switch, to its customers. The product integrates eight silicon photonics based 6.4-Tbps optical engines with Broadcom's best-in-class StrataXGS Tomahawk 5 switch chip. Bailly enables the optical interconnect to operate at 70% lower power consumption and delivers an 8x improvement in silicon area efficiency as compared to pluggable transceiver solutions.

09:12 EDT NeuroMetrix announces publication of study on DPNCheck - NeuroMetrix noted the recent publication of a large study demonstrating that DPNCheck combined with standard EKG or DPNCheck alone accurately detects diabetic peripheral neuropathy. Hayashi and colleagues evaluated 167 patients with Type 1 or Type 2 diabetes. The reference standard for DPN was a gold standard nerve conduction study. The authors developed a predictive formula based on DPNCheck measurements, patient age and the coefficient of variation of R-R intervals which quantifies autonomic function and is a standard output of EKG machines. DPNCheck combined with CVR-R had high diagnostic performance with an area under the receiver operating curve of 0.88. Similar performance was reported when using just DPNCheck to diagnose DPN. The authors concluded "The use of DPNCheck and electrocardiogram would make the diagnosis of DPN simple, ubiquitous, and with high reproducibility and reliability."

09:10 EDT Bright Green to install 102-megawatt solar field for Dalsem project - Bright Green Corporation announced that BGXX will install a 102-megawatt solar field to power the electricity and heating requirements for the new $250 million Dalsem expansion project and commits to switch the existing facility that currently burns natural gas and heavy oil to solar. This ensures that the BGXX production and drug manufacturing requirements in Grants, New Mexico are carbon neutral. The company started the bid process and is working with several Solar Installation Companies domiciled in New Mexico to install a 102-Megawatt Solar Power Generation field. The successful bid will also include a Power Purchase Agreement from local utilities to purchase the excess power during peak times. The Company has committed and will install three high efficiency boilers manufactured from Precision Boilers, LLC in Morristown, Tennessee for their high efficiency 40 megawatt boilers to be powered by the new solar field. The electric boilers will heat hot water that is stored in massive hot water storage tanks at 200 degrees to be used for the heating requirements during low sun periods. The VP panels will be manufactured from Singapore based Maxeon Solar Technologies for the new state-of-the-art solar manufacturing plant in Albuquerque, New Mexico. BGXX has committed to clean renewable energy to supply the massive heat and electricity loads to the 1 million existing and 7 million sq. ft. expansion. Baker Tilly has completed the modeling for construction cost and related construction jobs for the EB-5 investment opportunity. The cost savings over the 30-year life span of the equipment will be in the hundreds of millions of dollars the Company estimates. In addition to the EB-5 funding, additional financing, if needed for the project, will be derived from federal infrastructure grants, loans and margining supply contracts for the BGXX, Drugs Made in America platform for this particular rural project. The building out of the solar field will take about 30 months and this will allow the company to better manage their EB-5 investment jobs creation opportuinity.

09:07 EDT Y-mAbs Therapeutics CFO Bo Kruse resigns - Y-mAbs Therapeutics announced that CFO, Bo Kruse, has notified the Company of his resignation. Y-mAbs has commenced a search process for a successor. Mr. Kruse will remain in the CFO role until his successor is identified and joins the Company. He will then continue as a non-executive employee from the time his successor joins the Company through July 31, 2024, after which it is expected that Mr. Kruse will be available to the Company for a period of time to support a smooth transition of the CFO role.

09:06 EDT Sprout Social appoints Crystal Boysen as CPO - Sprout Social (SPT) announced the appointment of Crystal Boysen to chief people officer, effective March 25, 2024. As CPO, Boysen will oversee Sprout's global people function and have an essential role in building and elevating Sprout's world-class team. Prior to Sprout, Boysen was the CPO at Vimeo (VMEO).

09:04 EDT Cellebrite unveils Cellebrite Endpoint Inspector SaaS - Cellebrite DI unveils Cellebrite Endpoint Inspector SaaS. This enhanced delivery model of the Endpoint Inspector product offers enterprise customers and eDiscovery service providers next-generation digital forensic capabilities that enable the streamlined collection and analysis of data from diverse remote devices, all within a unified, consent-based, secure framework.

09:03 EDT Textainer closes acquisition by Stonepeak - Textainer Group completed the previously announced acquisition of Textainer by investment vehicles managed by Stonepeak. All common shares of Textainer converted into the right to receive $50.00 per share in cash. The per share consideration paid to shareholders on the JSE will be in South African Rand at an exchange rate of 18.98821 Rand for each USD 1.00. The common shares, which trade on the New York Stock Exchange under the ticker symbol "TGH", were suspended from trading today prior to the open of market and will be delisted from the NYSE within 10 days. In addition, Textainer intends to file a certification on Form 15F with the SEC requesting the termination of registration of the common shares under Section 12(g) of the Securities Exchange Act of 1934, as amended and the suspension of Textainer's reporting obligations under Section 13 of the Exchange Act with respect to the common shares. Also on March 14, 2024, after the closing of the acquisition, Textainer issued a notice of redemption for all its 7.000% Series A Cumulative Redeemable Perpetual Preference Shares and the corresponding redemption of each depositary share representing a 1/1000th interest in each such share, CUSIP 88314W204, and 6.250% Series B Cumulative Redeemable Perpetual Preference Shares and the corresponding redemption of each depositary share representing a 1/1000th interest in each such share, CUSIP 88314W303. The redemption date for the Preference Shares and corresponding depositary shares will be April 15, 2024. The redemption price for each Series A Preference Shares will be $25,150.69 and each Series B Preference Share will be $25,134.55. The corresponding depositary share redemption price will be $25.15 per Series A Depositary Share and $25.13 per Series B Depositary Share. Regular quarterly dividends on the Preference Shares and depositary shares are payable March 15, 2024, to each holder of record on March 1, 2024. No dividends on the Preference Shares and depositary shares will accrue on or after the Redemption Date, nor will any interest accrue on amounts held to pay the redemption price. Following the redemption of the Preference Shares and depositary shares, Textainer will request that the NYSE delist the depositary shares. In addition, Textainer intends to file a certification on Form 15F with the SEC requesting the termination of registration of the Series A Preference Shares and the Series B Preference Shares under Section 12(g) of the Exchange Act and the suspension of Textainer's reporting obligations under Section 13 of the Exchange Act with respect to the Preference Shares.

08:59 EDT Charles Schwab reports total client assets $8.88T up 20% as of February-end - The Charles Schwab Corporation released its Monthly Activity Report today. Company highlights for February 2024 include: Core net new assets brought to the company by new and existing clients totaled $33.4 B. Net new assets excluding mutual fund clearing totaled $31.1B. Reports total client assets were $8.88T as of month-end February, up 20% from February 2023 and up 4% versus January 2024; Transactional sweep cash ended February 2024 at $403.2B representing a decrease of $2.9B versus the prior month.With the company's diversified financial model benefiting from rising equity markets and stronger client trading activity to start the year, the company anticipates first-quarter sequential revenue growth of approximately 5% to 6% and adjusted pre-tax profit margin expansion of nearly four percentage points versus the fourth quarter as the full impact of the late 2023 incremental cost savings are realized. 1Q24 GAAP pre-tax profit margin is currently expected to expand by more than 900 basis points versus 4Q23.

08:56 EDT Vital Energy announces offering of $575M of senior notes - Vital Energy intends to offer, subject to market and other conditions, $575.0 million in aggregate principal amount of senior notes due 2032 in a private placement to eligible purchasers. The Company intends to use the net proceeds of the Offering, if completed, together with existing corporate liquidity, to fund the purchase for cash of up to $475.0 million aggregate principal amount of our 10.125% senior notes due 2028 and $75.0 million aggregate principal amount of our 9.750% senior notes due 2030 in the cash tender offers the Company commenced pursuant to an offer to purchase dated March 14, 2024, pay fees and expenses incurred therewith and/or repay borrowings outstanding under our senior secured credit facility. The senior notes will be senior unsecured obligations of the Company and will be guaranteed on a senior unsecured basis by Vital Midstream Services, LLC, a subsidiary of the Company, and certain of its future subsidiaries.

08:52 EDT SciSparc doses first patient in Autism Spectrum Disorder trial - SciSparc has successfully dosed the first patient in its SCI-210 clinical trial at the Soroka Medical Center for pediatric patients who have Autism Spectrum Disorder. This significant milestone follows the Company's recent announcement about the successful delivery of its innovative SCI-210 treatment to the clinical trial site, enabling the commencement of dosing. SciSparc's proprietary SCI-210 treatment combines cannabidiol-rich oil and CannAmide, SciSparc's proprietary palmitoylethanolamide-based tablets. The dosing of the first patient signifies the transition from preparatory phases to active treatment evaluation in the quest to offer a more effective and safe treatment option for ASD.

08:49 EDT GRI Bio announces notice of allowance for Canadian patent - GRI Bio announced that the Canadian Intellectual Property Office has issued a notice of allowance for Patent Application No. 3,007,970 titled, "Prevention and Treatment of Inflammatory Conditions." A patent from the recently allowed application is expected to be issued in the coming months. When issued, the patent will cover claims including compositions and methods for modulating type 2 and/or type 1 invariant NKT cells in the prevention and treatment of inflammatory conditions of the liver. More specifically, when issued the patent will cover the prevention and treatment of inflammatory and fibrotic conditions through the administration of a Retinoic Acid Receptor agonist that inhibits iNKT cells and the administration of an RAR agonist that inhibits the activity of iNKT cells in a subject.

08:48 EDT Baker Hughes announces 'breakthrough' in flare emissions monitoring - Baker Hughes (BKR) has announced a breakthrough in flare emissions monitoring following a collaboration with bp (BP). Using Baker Hughes' emissions abatement technology, flare.IQ, bp is quantifying methane emissions from its flares, a new application for the upstream oil and gas sector. With no universally accepted solution to quantifying methane emissions from flares, bp and Baker Hughes conducted one of the largest ever full-scale studies of flare combustion, including testing a range of flares under challenging conditions and verifying the accuracy of flare.IQ technology. Now, acting on real-time data from flare.IQ at 65 flares across seven regions, bp can carry out early interventions and reduce emissions from flaring.

08:47 EDT SRIVARU nears completion of EV motorcycle manufacturing facility - SRIVARU Holding is near completion of its new manufacturing facility in Coimbatore, India, which is expected to be fully operational in April 2024. We expect the new manufacturing facility will initially provide the Company with the capacity to produce over 2,000 bikes per month, operating just a single shift and single line. The facility incorporates advanced automation systems, expected to significantly enhance manufacturing efficiency and operating margins. The new facility's production capacity has been designed to be able to be expanded with minimal capex requirements through additional lines and multiple shifts, which could support production of more than 50,000/units per year.

08:44 EDT AMMO launches multi-item cart, single payment portal on GunBroker.com - AMMO announces the official launch of new tools to enhance the customer experience at GunBroker.com that incorporates a new multi-item cart and single payment portal. The multi-item cart allows customers to purchase multiple items from different sellers, with a single checkout and payment. Previously, buying more than one item required a corresponding number of checkouts for each purchase. Firearms and accessories, such as holsters, magazines, ammunition, etc., will all be incorporated into the new system that will require users only enter their federal firearms license, payment and shipping information one time. Any coupon or discounts offered by sellers, applied once, will automatically be applied to all eligible items. The cart will display orders requiring payment from auctions that customers have won along with immediate purchase items the user added to the cart. All these items can be checked out and paid for together.

08:43 EDT Milestone Scientific commences sales of CompuFlo Epidural Disposables - Milestone Scientific has commenced sales of CompuFlo(R) Epidural disposables to Omaha Pain Physicians, a comprehensive medical pain management center in Omaha, NE. Omaha Pain Physicians is focused on treating patients with acute and chronic pain. Adoption of the technology by this clinic follows a successful evaluation process by its founder and medical director, Dr. Matthew Stottle, an interventional pain medicine physician, who is board-certified by the American Board of Anesthesiology in both anesthesiology and pain medicine. Dr. Matthew Stottle completed 10 cases using the CompuFlo Epidural system at Omaha Pain Physicians, in which he reported 100% success. The evaluation included Epidural Steroid Injection procedures within the lumbar, thoracic and cervical thoracic junction of the spine.

08:41 EDT 180 Life Sciences regains compliance with Nasdaq requirement - 180 Life Sciences Corp. received a letter on March 13, 2024 from The Nasdaq Stock Market indicating that the Company has regained full compliance with the minimum bid price for continued listing on the Nasdaq pursuant to Nasdaq Listing Rule 5550(a)(2). As indicated in the letter, Nasdaq determined that for 10 consecutive business days, the closing bid price of the Company's common stock was at or above $1.00 per share. Accordingly, the Company has regained compliance with the Minimum Bid Price Requirement.

08:40 EDT GeneDx to present data on exome at ACMG meeting - GeneDx announced its scientific contributions at the 2024 American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting. Across one platform presentation, an industry symposium and six poster presentations, including one selected as a "Rapid Fire Poster Session," an invitation-only presentation of the top 20 ACMG posters, GeneDx continues to demonstrate its industry leadership in shaping the future landscape of genomics. One of the GeneDx poster sessions includes data demonstrating the ability of exome sequencing to detect small copy number variants below the reporting threshold of chromosomal microarray and the detection of CNVs at nearly 99% concordance with CMA. These findings represent improved data quality from pipeline and platform improvements. Combined with its ability to identify many other types of variants compared to CMA and its nearly three times higher diagnostic yield, these findings demonstrate the clinical superiority of an exome over CMA. These data support the current clinical guidelines recommending exome as a first-tier test and represent GeneDx's groundbreaking approach to genomic data analysis and interpretation, aimed at eliminating the need for additional tests when ordering exome first. In its platform presentation, GeneDx will highlight its newly developed statistical approach for predicting the impact of many missense variants with a precision of 99%. This proof-of-concept research has the potential to decrease the variants of unknown significance rate and drive greater operational efficiency and diagnostic precision by decreasing the number of variants requiring additional vetting. In addition to its technological and scientific advancements, GeneDx is committed to democratizing access to genomic testing by eliminating barriers and unlocking the bottlenecks of care. Through an industry-sponsored session, GeneDx will explore the gap between the availability of the medical genetics workforce and the genetic testing needs of pediatric patients. This session features a discussion comparing viewpoints and opportunities around non-geneticists ordering genomic sequencing as part of routine care, with the goal of improving patient outcomes.

08:37 EDT Scorpius Holdings accepted as member of BioMaP-Consortium - Scorpius Holdings has been accepted into the Biopharmaceutical Manufacturing Preparedness Consortium, a part of the National Biopharmaceutical Manufacturing Partnership. The BioMap-Consortium has a $20 billion funding ceiling, through which it provides growth funding, as well as streamlined access to servicing government-funded manufacturing programs. The BioMaP-Consortium supports the Biomedical Advanced Research and Development Authority and is comprised of industry partners across the drug and vaccine manufacturing supply chain, including manufacturers of raw materials and consumables, developers of innovative manufacturing technologies, and suppliers of fill finish services. This consortium seeks to expand the industrial and manufacturing base for medical countermeasures to include the requisite capabilities, flexibilities, and strategies to secure needed medical supplies to meet the nation's public health preparedness and response requirements.

08:33 EDT Iveco Group, Ford Trucks sign MOU to examine potential synergies - Ford Trucks, the heavy commercial brand of Ford Otosan, and IVECO, have signed a non-binding Memorandum of Understanding to explore a potential collaboration on development of a new cabin for heavy-duty commercial vehicles. The non-binding MoU is a preliminary step in assessing the potential for the two companies to cooperate in the co-development of new products and technologies, encompassing components and systems within the cabin. This agreement has the aim of enhancing competitiveness and improving solutions in compliance with the EU Direct Vision Standard and improving aerodynamics for CO2 reduction through the development of a mutually beneficial partnership between Ford Trucks and IVECO.

08:33 EDT OSI Systems receives $15M order from healthcare OEM - OSI Systems announced that its optoelectronics and manufacturing division has received an order for approximately $15M to provide critical electronic sub-assemblies for a healthcare original equipment manufacturer, or OEM, known for innovative and specialized medical solutions.

08:31 EDT GoHealth sees 2024 revenue flat, operating cash flow flat to slightly up - On the Q4 earnings conference call, GoHealth said it expects 2024 submission volume to grow in line with the overall Medicare market. Additionally, it expects revenue to be flat year-over-year with incremental operating efficiency, resulting in modest margin expansion, and expects cash flow from operations flat to slightly up.

08:27 EDT Iveco Group reveals four key pillars for future growth - The Group's pathway is underpinned by four key pillars: Innovation, Financial Discipline, Partnerships and Sustainability. These pillars drive the success of each Business Unit and enable the overall Group to collectively withstand external challenges and focused spending. Innovation: Iveco Group fully backs the investments it has made since operating as an independent Company and will invest over EUR 5.5 billion from 2024 to 2028 in order to stay on the front end of the very fast innovation curve. The Company is driving Innovation in three key areas: Energy Transition, Artificial Intelligence & Software Defined Vehicles, and Autonomous Driving. In Energy Transition, the Company reaffirms its aim to reach net zero carbon emissions by 2040. Instrumental to this achievement is Iveco Group's multi-propulsion approach that includes green and zero-emission solutions. These will be backed by innovative pay-per-use business models, such as GATE - Green & Advanced Transport Ecosystem. Initially launched in Italy in mid-2023, with a focus on Iveco Group's ZEV, GATE's five-year ambition is to scale up, evolving into a brand-agnostic platform open to other OEMs' vehicles. Artificial Intelligence is central to Iveco Group's customer-centred innovations, with Generative AI enabling significant advancements in areas such as data analysis, machine-human interaction, and software development. Software Defined Vehicles, powered by AI algorithms, are set to revolutionise the industry, simplify vehicle updates, and increase customer productivity. To remain on top of these trends, Iveco Group has inaugurated its own Software & Analytics Lab, with plans for a team of 500 specialised engineers in the coming years. Iveco Group is already testing Autonomous Driving on public roads in Europe. For this development and its swift commercialisation, collaboration with PLUS, a global provider of self-driving truck technology, alongside other truck OEMs is fundamental. These advancements offer already today highly automated driver assistance systems to drivers and fleet owners. Financial Discipline" Iveco Group is committed to increasing its cash generation potential and reducing seasonality where possible. At the same time, the continued focus on cost optimization and efficiency will further decrease product costs and maintain a lean SG&A structure, that by 2028 is projected to be reduced by 50 basis points versus 2023. The Company's prior operational excellence programme set a target to save EUR 1 billion in the 2019-2026 timeframe. At the end of 2023, Iveco Group was in line with its goal, having set aside EUR 300 million in operational efficiencies, plus another EUR 600 million of improved profitability in terms of volumes, mix and pricing. With the new plan, starting with 2024, the Company is committing to EUR 1 billion of efficiencies, split in EUR 600 million by 2026 and another EUR 400 million by 2028. This will be accomplished through the implementation of a detailed set of initiatives, aimed at reducing product complexity, optimizing best-cost-countries sourcing, maximizing manufacturing efficiencies, and exploiting several commercial and technical levers. In terms of investments, the EUR 5.5 billion projected over the next five years are split between Capex and capitalized R&D. More than 50% of total investments is not bound by compliance or regulatory restrictions, thus allowing for swift adaptation to market dynamics as and when necessary. The Group will prioritize investments that offer attractive returns and will continue to explore cooperation opportunities to optimize spending, demonstrating a disciplined investment profile. Partnerships: Iveco Group is extending and deepening its partnership with Hyundai Motor Company in the area of electric heavy-duty truck solutions, including both battery electric trucks and fuel cell electric trucks for European markets. By leveraging the advanced technologies and assets of each party, the two companies expect to accelerate the transition to a sustainable future. Since initiating their partnership in March 2022, Hyundai Motor and Iveco Group have achieved a series of significant milestones. Notably, in September 2022, they unveiled the first IVECO eDaily Fuel Cell Electric Vehicle at the IAA Transportation event in Hanover. This was followed by the debut of the IVECO BUS E-WAY H2 in October 2023 at Busworld in Brussels. Most recently, in February of this year, the two companies announced the signing of a supply agreement for an IVECO-badged all-electric light commercial vehicle for Europe, based on Hyundai's eLCV platform. Also today, IVECO and Ford Trucks, the heavy commercial vehicles brand of Ford Otosan, announce a non-binding Memorandum of Understanding to explore a collaboration on the development of a joint cabin structure for heavy-duty trucks compliant with the new regulations coming into force in 2028/2029. This is a preliminary step in the co-development of new products and technologies, encompassing components and systems within the cabin. Sustainability: Sustainability is a key pillar for Iveco Group. The Group's actions are designed to have a positive impact on its people and on broader society. Building on early achievements, Iveco Group has set even more ambitious Sustainability targets, including: By 2026, 100% of total electricity consumption will come from renewable sources. This target's deadline was anticipated from 2030 to 2026; The Group aims to recycle 75% of industrial water at company plants worldwide by 2026, versus the previous target of 60%; The new 2028 target for gender parity is for 30% of office positions to be held by women. Therefore, the Group will widen and raise its scope to include all female employees across every phase of their career.

08:24 EDT Autonomix completes first three procedures in human trial of RF ablation - Autonomix Medical announced the safe completion of the first three patient procedures for its proof-of-concept human clinical trial evaluating the use of transvascular RF ablation for the treatment of pancreatic cancer pain. The primary objective of the PoC human clinical trial is to successfully ablate relevant somatic nerves and mitigate pain in patients with pancreatic cancer pain utilizing RF ablation in a transvascular approach to the nerves in the region. Twenty subjects will be enrolled at one clinical trial site for the trial. Confirmation of suitability will be affirmed by the primary oncology service caring for the patients. Up to 5 additional patients will be included and treated according to protocol to ensure the physician's familiarity with the procedure. However, they will not be included in the analysis of the trial objectives. Enrollment is expected to be completed before the end of 2024.

08:22 EDT Applied Digital secures contract with Together AI - Applied Digital announced the onboarding of another AI customer, Together AI. Applied Digital received a contract prepayment of $18 million as part of the $75 million contract, in connection with which it has fully onboarded one compute cluster of GPUs and has provided access to its second cluster. Together AI is a research-driven artificial intelligence company contributing to leading open-source research, models, and datasets to advance the frontier of AI. The company's decentralized cloud services empower developers and researchers at organizations of all sizes to train, fine-tune, and deploy generative AI models. Together AI will be running on Applied Digital's dynamic computing ecosystem, custom-built to meet the rigors of AI's demanding tasks and data-rich optimizations. The structure boasts H100 GPUs and is seamlessly interconnected via high-speed InfiniBand fabric, delivering an aggregated bandwidth of 3.2 Tbps. The communication between the GPUs will be enhanced by NVIDIA's NVLink technology, adhering to an optimized Rail Design.

08:19 EDT Rumble Cloud enters partnership with ACP CreativIT - Rumble announced a strategic partnership with ACP CreativIT. This partnership will strengthen Rumble Cloud's focus on North America while expanding its offering with a wider range of complementary services and solutions using the Rumble Cloud infrastructure. The combined effort allows Rumble Cloud customers to optimize their IT operations and business continuity while enhancing data privacy and security.

08:17 EDT Zscaler announces AI innovations for Zscaler Zero Trust Exchange data - Zscaler announced another leap forward in artificial intelligence innovations that extends the Zscaler Zero Trust Exchange data, from more than 400 billion daily Zscaler transactions with Avalor's Data Fabric for Security with over 150 pre-built integrations enabling customers to proactively identify and predict critical vulnerabilities as well as improve operational efficiencies. By leveraging its massive data foundation, Zscaler is poised to transform the AI capabilities for the cybersecurity industry to not only enable organizations to mitigate risks and optimize performance but also pave the way for zero-touch operations. The rapid advancement of AI will have pivotal impacts to the cybersecurity industry and to effectively combat AI-led threats, organizations must fully harness their currently isolated security data at massive scale. Zscaler's 16 years of leadership operating the world's largest cloud security platform has allowed it to leverage a massive data set to develop its pioneering AI-driven solutions, including Zscaler Risk360 and Zscaler Business Insights, which set a new benchmark for proactive cybersecurity and business intelligence.

08:15 EDT Charles River and Navega announce an AAV9 production program agreement - Charles River Laboratories and Navega Therapeutics announced an AAV9 production program agreement. As part of Charles River's Cell and Gene Therapy, CGT, Accelerator Program, CAP, Navega will have access to established contract development and manufacturing or CDMO, capabilities and advisory services to produce an adeno-associated virus, AAV-based gene therapy, NT-Z001, for Phase I clinical trials.Navega is pursuing an approach for treatment of chronic pain associated with rare diseases such as small fiber neuropathy and primary erythromelalgia by harnessing the precision of its AI-enabled zinc-finger epigenome regulation platform. Navega's epigenetic therapy addresses a gain-of-function mutation in the Nav 1.7 gene, linked to inherited erythromelalgia, small fiber neuropathy and other chronic, debilitating pain disorders. With over 17 million Americans living with high-impact chronic pain, Navega's non-opioid gene therapy for chronic pain may also be used in other intractable pain indications, including neuropathic and inflammatory pain. Plasmid and Viral Vector CDMO Solutions To bring NT-Z001 to clinic, Navega will leverage Charles River's off-the-shelf plasmid products, custom plasmid capabilities, and Good Manufacturing Practice or GMP-grade AAV production. "The collaboration with Navega will tap into our premier gene therapy CDMO capabilities and robust AAV offerings. We are thrilled that our expertise will help bring Navega's gene therapy closer to patients suffering with chronic pain." - Kerstin Dolph, Corporate Senior Vice President, Biologics Solutions, Charles River

08:14 EDT Metals Company 'applauds' letter on ratifying UNCLOS treaty - TMC the metals company welcomed a letter from around 350 former U.S. government officials and military officers urging the U.S. Senate to re-evaluate a formal vote on ratifying the United Nations Convention of the Law of the Sea treaty. The letter, which follows this week's introduction of the Responsible Use of Seafloor Resources Act in Congress, was signed by around 189 American ambassadors, 73 generals, 50 admirals, four directors of national intelligence and scores of other distinguished supporters. The co-signatories warned how "China and Russia have taken advantage of our absence to work actively to undermine critical United States economic and national security interests," and that the U.S. had "already lost two of our four 'USA' designated deep seabed mine sites, each containing a trillion dollars in value of the strategic minerals of copper, nickel, cobalt, manganese and rare earths" needed for national security and the energy transition. Since the turn of the decade, increasing U.S. investment in and prioritization of offshore mineral exploration has been codified through the formation of various bodies including the National Ocean Mapping, Exploration, and Characterization Council in 2020, the Ocean Policy Committee formed via direction of the National Defense Authorization Act in 2021, and the declaration of outer limits of the U.S. extended continental shelf in 2023 which declared U.S. rights to approximately one million square kilometers of subsea territory in an effort to protect future economic opportunities. Although the U.S. has yet to ratify UNCLOS - a legislative step that would enable it to access the vast, untapped critical minerals found in seafloor nodules in international waters - it can still process and refine critical minerals extracted from polymetallic nodules collected in international waters.

08:11 EDT Keros Therapeutics announces Fast Track designation for KER-050 - Keros Therapeutics announced that the U.S. Food and Drug Administration has granted Fast Track designation for KER-050 for the treatment of anemia in adult patients with very low-, low-, or intermediate-risk myelodysplastic syndromes.

08:10 EDT Braskem to use feedstock to make bio-attributed and bio-circular polypropylene - Shell Chemicals recently started to supply Braskem with bio-attributed and bio-circular propylene feedstocks, based on a mass balance approach and independently certified by a third party. Braskem will utilize such feedstocks for the manufacture of bio-attributed and bio-circular polypropylene enabling more sustainable options for growing consumer demand in the packaging, film, automotive, and consumer goods markets. Mark Nikolich, Vice President of Olefins and Polyolefins, Braskem North America stated, "Braskem is a leader in the innovation and production of bio-based materials, and we continue to see demand grow for more renewable solutions in our markets. In January 2023, we communicated the evaluation of a Braskem-led project to produce bio-based propylene in the U.S. With today's announcement, we will continue to focus our work on sources of sustainable propylene, in this case, bio-attributed and bio-circular, to support our polypropylene clients in meeting their carbon reduction and circularity goals. This is possible because of forward-thinking suppliers like Shell. Ultimately, we believe that these different renewable solutions are complementary and important steps forward as the plastics industry evolves to a more sustainable future. We will continue to develop and provide solutions to support our global clients in reaching their sustainability goals."

08:09 EDT 60 Degrees announces FDA communication on trial protocol submission - 60 Degrees announced that the U.S. Food and Drug Administration has communicated its intention to send any comments regarding the Company's babesiosis trial within the month of April, 2024, rather than March, 2024 as anticipated by the Company. The protocol submission mechanism as directed by the FDA, i.e., under the Company's existing Investigational New Drug application, technically does not require a response from the FDA within a specified time frame. The Company is continuing preparations for a June 1, 2024 start date as previously communicated. Tafenoquine is the active ingredient in an anti-malarial approved by the FDA in 2018 and is indicated for the prophylaxis of malaria in patients aged 18 years of age and older

08:05 EDT Lichen China subsidiary in Singapore begins operations - Lichen China announced its expansion into international markets. Lichen China established its subsidiary in Singapore in December 2023 and has now officially started operations. The company has appointed Robert Bodenstein, Chair of the International Council of Management Consulting Institutes, as its new independent director, as the first step in expanding its reach into Southeast Asia.

08:03 EDT Home Depot expands Pro ecosystem, to open four new distribution centers - The Home Depot is opening four new distribution centers, expanding its pro ecosystem to Detroit, southern Los Angeles, San Antonio and Toronto in 2024. The new facilities are a key component of The Home Depot's strategy to better serve pro customers - whether they're the pro customers that The Home Depot has traditionally served through the store, or pros working on larger, more complex projects. The new distribution centers will stock large, bulky merchandise like lumber, insulation, roofing shingles and more. With a network of distribution centers stocking a variety of product types, pros can order job lot quantities of the products they need to complete their entire projects, delivered directly to their job sites. The new distribution centers are expected to open in the first half of the year.

07:54 EDT Ivanhoe Electric announces application of CGI software at Tintic Project - Ivanhoe Electric and its subsidiary, Computational Geosciences are pleased to provide an update on CGI's proprietary software applications used to interpret Typhoon data. CGI continually improves its proprietary algorithms, leveraging advanced machine learning data processing technologies, to deliver higher quality Typhoon geophysical inversion models with quicker turnaround times. Ivanhoe Electric owns 94% of CGI. Taylor Melvin, President and CEO, commented: "We believe Computational Geosciences has the mining industry's most powerful machine learning software application available. CGI's proprietary algorithms are capable of analyzing the massive amounts of data generated by our ground-based Typhoon geophysical surveying system. We are excited to apply the same cutting-edge version of CGI's software at Tintic that we are currently using in Saudi Arabia and at our other more recent American exploration projects. CGI's latest software improvements allow us to analyze more data, more quickly, and generate clearer models to guide future discovery. We are now beginning to test the refined targets around the historically productive Mammoth copper-gold-silver mine at Tintic, Utah, with directional drilling equipment." Through continuous research and development, CGI's innovations harnesses the power of machine learning algorithms to improve data processing capacity, processing times, and to enhance the signal-to-noise ratio of input data through improved data utilization. This effort has led to faster inversion model delivery times and improved three-dimensional inversion models. CGI continues to lead the transformation of geophysical data processing and three-dimensional inversion.

07:51 EDT Dundee Precious Metals announces renewal of normal course issuer bid - Dundee Precious Metals announced that the Toronto Stock Exchange accepted its notice of intention to renew its normal course issuer bid to purchase certain of its common shares through the facilities of the TSX. The Company commenced a normal course issuer bid on March 1, 2023, which terminated on February 28, 2024. Under the Previous Bid, the Company sought and obtained approval to purchase up to 16.5 million Shares, being approximately 9.8% of the Company's public float as of February 16, 2023. The Company repurchased 9,186,706 Shares under the Previous Bid. The number of Shares that may be purchased during the period of the New Bid, which will commence on March 18, 2024, and terminate on March 17, 2025, will not exceed 15.5 million Shares, being approximately 9.8% of the Company's public float of Common Shares as of March 6, 2024. All purchases made pursuant to the New Bid will be made through the facilities of the TSX or other alternative trading systems in accordance with applicable Canadian securities laws and Shares purchased pursuant to the New Bid will be cancelled. Pursuant to the terms of the New Bid, the Company will not acquire on any given trading day more than 137,811 Shares, representing 25% of the average daily trading volume of Shares for the most recently completed six-month period, being 551,244 Shares, other than block purchase exceptions.

07:49 EDT Purple Biotech reports preclinical proof of concept for tribody platform tech - Purple Biotech reported preclinical proof of concept data for its conditionally-activated tri-specific antibody platform. Using 5T4-expressing lung cancer PDE model, where the immune cells and the tumor cells are derived from the same patient, the studies showed a synergistic effect of the T cell engager and NK cell engager arms. While each bispecific agent, 5T4xCD3 or 5T4xNKG2A, showed only low response, the tribody platform's leading candidate IM1240 having both engagers in one product, demonstrated a synergistic strong anti-tumor response. This effect is activated through the presence of 5T4 positive tumor cells. The advantage of the 5T4 arm was also validated using in-vitro PBMC-mediated cytotoxicity of cancer cell line studies which demonstrated 5T4-specific effect. While cytotoxicity at pM range was observed in 5T4-positive lung and breast cancer cells, no effect was observed against 5T4-negative cancer cells. Purple Biotech's cleavable capping technology confines the compound's therapeutic activity to the local tumor micro environment, which increases the anticipated therapeutic window in patients. This cap is attached to the anti-CD3 moiety and blocks its interaction with circulating CD3 positive T cells, thereby impeding potential off-tumor adverse reactions and also improving PK properties. The cap is designed to be cleaved off by multiple TME-specific proteases, which increase the likelihood for cleavage by many tumor types. Upon removal of this cap, the anti-CD3 moiety of the molecule is freed to bind and activate T lymphocytes against the tumor via CD3.

07:46 EDT DraftKings launches 'My Stat Sheet' tool - DraftKings unveiled My Stat Sheet, a gaming tool that gives players the ability to assess, track and interact with their personal stats through intuitive charts and information that will help empower players to make data-driven decisions on their own play and therefore promote responsible gaming. This new feature is now available across all DraftKings and Golden Nugget products. Customers can view time spent on the platform, deposits, withdrawals, contest involvement, wagers placed, and net win/loss across monthly, yearly, and lifetime views through intuitive charts and filtering options. My Stat Sheet is accessible to all customers through all DraftKings platforms.

07:44 EDT Microbix Biosystems says partner Sequel Pharma executes CDMO agreement - Microbix Biosystems announces that its funding and commercialization partner, Sequel Pharma, has executed, with support from Microbix, an agreement with a leading international contract development and manufacturing organization for production of the active ingredient of Kinlytic urokinase, a biologic drug for dissolving blood clots. Sequel is a U.S. based specialty pharma company with expertise in developing and commercializing niche drugs. It has committed to provide all funding needed to return Kinlytic to global markets, initially for the US$ 350 million U.S. market for dissolving clots in indwelling venous catheters. Kinlytic is an enzyme derived from human cell cultures that dissolves the material of a blood clot. Kinlytic is already approved for clinical use in the U.S. and the parties' work is to validate new manufacturing for the drug and to re-enter the market by way of a supplemental biologics licensing application. The referenced CDMO agreement is for all actions necessary to resume production of Kinlytic Drug Substance at a scale sufficient for the Catheter Clearance market. The CDMO has undertaken to complete this work over a timeframe specified by Sequel and in line with Microbix's disclosed project objectives. The work of the CDMO will be overseen by Sequel, with scientific and technical assistance from Microbix. It is Microbix's intention to update its shareholders on further Kinlytic-related achievements as they become meaningful. Anticipated future disclosures related to Kinlytic may include, among other matters, successful production of Drug Substance, contracting for manufacture of clinically-formulated drug, first production of Drug Product, and clinical, regulatory, or commercial milestones. It is anticipated that Microbix will make two to three Kinlytic-related news release disclosures each year between now and the filing of a sBLA for the project, which may occur in calendar 2026 or 2027.

07:42 EDT Renalytix's KidneyIntelX included in KDIGO 2024 Clinical Guideline - Renalytix announces that the KidneyIntelX In-Vitro Diagnostic test has been included in the final KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Diseases, published on March 13, 2024. In the release of the new guideline, timed to coincide with World Kidney Day on March 14, the KDIGO committee highlighted the role of risk prediction in guiding care for patients. In this context, KidneyIntelX is recommended for use as an externally validated tool for predicting disease progression in people with CKD stages G1-G3. The Guideline Work Group recognized that the progression of CKD can occur at all stages, and that in earlier stages of disease, understanding the risk of 40% decline in kidney function over a short term 5 years, as per the indicated use of KidneyIntelX, is important for guiding early intervention, particularly in people at intermediate or high risk for progression. Renalytix received FDA de-novo marketing authorization for kidneyintelX.dkd in June 2023 for use in assessment of the risk of progressive decline in kidney function in patients with CKD stages G1-G3 and Type 2 Diabetes. Subsequent to the release of the draft content of this updated guideline in July 2023, further evidence has been published from clinical utility and outcomes studies with a current enrollment of more than 9,000 patients with Type 2 Diabetes and CKD G1-G3. In January 2024, published outcomes data from an analysis of more than 2,500 patients with one year of follow-up demonstrated that providing clinicians access to KidneyIntelX risk assessment to inform care was associated with clinical actions that resulted in sustained reduction in eGFR decline, improved diabetes management and improved cardiovascular health.

07:36 EDT DocGo enters 10b5-1 trading plan for additional $10M stock repurchase program - DocGo announced that as of March 12, it has repurchased a total of 1.25M shares of its common stock at an average of $3.88 per share under its share repurchase program announced on January 31. Pursuant to the repurchase program, DocGo is authorized to purchase up to $36M of its common stock during a six-month period ending July 30. DocGo also announced that it has entered a 10b5-1 trading plan to facilitate repurchases of up to an additional $10M of its common stock under the repurchase program, which will enable the continued purchase of shares during the company's quarterly blackout period that begins on March 15. The 10b5-1 plan will run through May 6.

07:34 EDT Cybin announces end-of-Phase 2 meeting with FDA for CYB003 - Cybin announced an End-of-Phase 2 meeting with the FDA for CYB003, its deuterated psilocybin analog for the adjunctive treatment of Major Depressive Disorder, or MDD. This program will be the first ever adjunctive Phase 3 deuterated psilocybin analog depression study globally and follows the successful completion of the company's Phase 2 study in MDD completed at the end of 2023. The company has received minutes from its End-of-Phase-2 meeting with the FDA and reached alignment on its Phase 3 program design. The company intends to commence enrollment for the multinational, multisite Phase 3 program in mid-year 2024. Fifteen U.S. study sites have been targeted, all of which have experience running psychedelic clinical trials and are DEA Schedule I licensed. The preliminary targeting of specific study sites will serve to expedite site initiation. The company intends to add approximately eight additional sites in Europe. The company has engaged Worldwide Clinical Trials, a global, full-service contract research organization with deep expertise managing clinical trials for mental health conditions, including major depressive disorder. Worldwide has a track record of successful patient recruitment for psychedelic trials and global relationships with investigative sites.

07:28 EDT Aura Minerals announces normal course issuer bid, BDR buyback program - Aura Minerals announces that the Toronto Stock Exchange has accepted the Company's notice of intention to launch a normal course issuer bid for its issued and outstanding common shares listed on the TSX. The Company is also announcing the concurrent launch of a buyback program for its Brazilian depositary receipts which are listed on the B3 S.A. - Brasil, Bolsa, Balcao, for the purchase of BDRs by the Company, its subsidiaries or investment vehicles. Under the NCIB, Aura Minerals may, if considered advisable, repurchase through the facilities of the TSX and/or alternative Canadian trading systems, from time to time during the currency of the NCIB, up to an aggregate of 2,261,426 Common Shares, representing 10% of the "public float" as of March 6, 2024, subject to the normal terms and limitations of such bids. The Company may commence purchases of Common Shares under the NCIB on March 18, 2024, and the NCIB will remain in effect until the earliest of: March 17, 2025, the date upon which Aura Minerals acquires the maximum number of Common Shares permitted under the NCIB, and the date upon which Aura Minerals provides written notice of termination of the NCIB to the TSX. Under the TSX rules, the Company may purchase up to 2,657 Common Shares on the TSX during any trading day, which represents 25% of the average daily trading volume of 10,631 Common Shares on the TSX during the six months ended February 29, 2024, other than purchases made pursuant to the block purchase exception. The actual number of Common Shares which may be purchased pursuant to the NCIB and the timing of any such purchases will be determined by the management of the Company, subject to applicable law and the rules of the TSX. Aura Minerals intends to concurrently launch a buyback program for its BDRs which are listed on the B3. Each BDR represents one Common Share. Under the BDR Buyback Program, the Company may purchase from time to time over 12 months, up to an aggregate of 2,261,426 BDRs, representing 10% of the "public float" as of March 6, 2024. Purchases of BDRs under the BDR Buyback Program are expected to be made by BTG Pactual Corretora de Titulos e Valores Mobiliarios S.A. through the facilities of the B3. The BDR Buyback Program is not intended to discontinue the Company's BDR program, or cancel the Company's registration with CVM as a foreign issuer registered as a category "A" publicly-held company. As of March 6, 2024, the Company had 72,237,003 issued and outstanding common shares and a "public float" of 22,614,260 Common Shares. The Company believes that the purchases are in the best interest of the Company and constitute a desirable use of its funds.

07:24 EDT Enthusiast Gaming's Pocket Gamer Connects to host PGC San Francisco - Enthusiast Gaming Holdings announced that its next live event Pocket Gamer Connects will take place in San Francisco on March 18-19. Being held immediately prior to the Game Developers Conference, PGC San Francisco is expected to draw a large crowd of video game developers, publishers and other industry professionals to connect, do business and learn from industry leaders. In partnership with Game Connection America, PGC San Francisco will feature talks, panels, and round-tables with experts from across the mobile, PC and console games space, plus match-making meetings, networking fringe events, a lively showcase expo, an indie pitching competition and more. Speakers and sponsors include executives from brands such as Netflix, Samsung, and Hasbro as well as representatives from top-grossing mobile games like Candy Crush, Honor of Kings, and Monopoly Go!

07:20 EDT Immuneering announces near-term milestone expectations - IMM-1-104: Initial data from multiple arms of the Phase 2a portion of Immuneering's Phase 1/2a study of IMM-1-104 expected in 2024. IMM-6-415: First patient in Phase 1/2a trial of IMM-6-415 expected to be dosed in March 2024.

07:17 EDT RumbleON unveils new three-year operating plan, Vision 2026 - RumbleOn unveiled its new three-year operating plan, Vision 2026, aimed to deliver annual revenue exceeding $1.7 B annual adjusted EBITDA of greater than $150 M and annual adjusted free cash flow of $90M or more by calendar year 2026. The three strategic pillars of Vision 2026 are: Operate the best performing dealerships in America. Leverage the RideNow Cash Offer Tool to accelerate growth of the pre-owned vehicle business. Allocate capital to maximize long-term per share value. "The first pillar is simple in its measurement, but broad in its execution," said Mike Kennedy, RumbleOn's Chief Executive Officer. "Our plan to operate the best performing dealerships in America will be measured on Net Profit and Customer Satisfaction. There's a lot that goes into delivering on these metrics, from simplifying and focusing our organization, attracting, retaining and properly incentivizing team members, and strengthening relationships with our OEM's. I'm excited about the progress we've already made. I've met with our largest OEM partners and they share my enthusiasm about the direction in which we're moving." ..."This three-year operating plan reflects input from our board, our team and my observations over the past few months," explained Kennedy. "... announcement to roll out the Vision 2026 plan in detail to analysts and employees today.

07:14 EDT PyroGenesis announces $450K contract for sale of plasma torch/furnace system - PyroGenesis Canada announced the signing of a contract with a U.S. structural materials entity engaged in the development of advanced cement materials. The first phase of the contract is approximately CDN$450,000 with the potential for future phases. Funded in part by the U.S. Department of Energy the name of the client will remain anonymous for confidentiality reasons. Under the terms of the contract, PyroGenesis will design and build a system tailored for lab-scale cement production applications. The system will include a plasma torch, a refractory furnace, and the required gas, power, and cooling components and peripherals. The system was contracted to provide the client the type of increased power and heat levels required for advanced cement development and testing, but without the fossil fuels and resultant emissions a gas-fueled system would normally generate. Subsequent phases may require a refractory lined reactor and other systems for additional development.

07:13 EDT Cyngn adds RobotLAB to distributor network - Cyngn announced its strategic partnership with RobotLAB, a robotics integrator that has deployed over 10,000 robots with customers across the globe. As a part of this partnership, RobotLAB will purchase ten fully-autonomous DriveMod Tuggers from Cyngn to establish an initial fleet for sale to end customers. The partnership paves the way for joint sales efforts that present exciting revenue growth opportunities for both companies. This collaboration expands the Cyngn Dealer Network, aimed at accelerating the widespread adoption of Cyngn's AI-powered autonomous vehicle solutions. RobotLAB recently announced its plans to further expand its scale by rolling out locations all across the country.

07:11 EDT AC Immune sees cash runway into at least 1Q26 - The Company had a total cash balance of CHF 103.1 million as of December 31, 2023, compared to a total cash balance of CHF 122.6 million as of December 31, 2022. On February 1, 2024, the Company received the milestone payment of CHF 14.8 million from Janssen for the commencement of ReTain, the ACI-35.030 Phase 2b clinical study. The Company's cash balance provides sufficient capital resources to progress into at least Q1 2026, assuming potential milestone payment of CHF 24.6 million related to achieving an undisclosed enrolment target for our ACI-35.030 and no other milestones.

07:08 EDT Perpetua Resources appoints Jon Cherry as CEO - Perpetua Resources' President and CEO, Laurel Sayer, has notified the Board of Directors of her intent to step down as President and CEO and a member of the Board of Directors effective March 14, 2024 and to retire effective April 1, 2025 after seven years of leading the company through the permitting process. The Board of Directors has appointed Jon Cherry to succeed Laurel Sayer as President and CEO of Perpetua Resources and as a member of the Board of Directors effective March 14, 2024. The Board of Directors has also appointed Jessica Largent, the CFO of Perpetua Resources, as a member of the Board of Directors. Sayer will serve as Senior Advisor to the CEO through March 2025. Jon Cherry joins Perpetua Resources with over 33 years of mining industry experience. He most recently served as Chairman, President, and CEO of PolyMet Mining. Before Polymet, Cherry served as a senior leader for Resolution Copper JV Project owned by Rio Tinto and BHP, General Manager of Rio Tinto's Eagle Mine and Senior Project Engineer at Rio Tinto Kennecott Utah Copper. In connection with the leadership transition, the Board of Directors appointed Cherry to fill the vacancy left by Sayer's retirement, effective March 14, 2024. The Board of Directors also appointed Perpetua Resources' CFO Jessica Largent as a Director, effective March 14, 2024. Largent was appointed CFO in April 2022 after joining the Perpetua team in February 2021 as Vice President, Finance and Investor Relations.

07:07 EDT Autolus Therapeutics says 'well capitalized' for pipeline development plans - Cash and cash equivalents at December 31, 2023 totaled $239.6 million, as compared to $382.4 million at December 31, 2023. Autolus estimates that, with its current cash and cash equivalents and proceeds received from the strategic alliance with BioNTech and the private placement and underwritten equity financing, it is well capitalized to drive the full launch and commercialization of obe-cel in r/r adult ALL as well as to advance its pipeline development plans, which includes providing runway to data in the first pivotal study of obe-cel in autoimmune disease.

07:03 EDT Monte Rosa Therapeutics announces anticipated upcoming milestones - Announce the recommended Phase 2 dose for the MRT-2359 Phase 1/2 study in Q2 2024 and report updated Phase 1 clinical results thereafter. Initiate the Phase 2 portion of the study before year-end. The Company is exploring Phase 2 expansion cohorts in high-prevalence c-MYC-driven tumors such as hormone receptor-positive breast cancer and prostate cancer, as well as tumor types and patient populations driven by L- and N-MYC including NSCLC, SCLC, and solid tumors with amplifications of L- and N-MYC. Submit an IND application for MRT-6160 in Q2 2024 and initiate a Phase 1 SAD/MAD study in healthy volunteers in mid-2024. Monte Rosa expects to subsequently initiate proof-of-concept studies in autoimmune diseases spanning gastroenterology, dermatology, rheumatology, and neurology indications. Submit an IND application for MRT-8102 in Q1 2025. Nominate a development candidate for the CDK2 preclinical program in 2024.

07:03 EDT Monte Rosa Therapeutics expects cash to fund operations into 1H26 - Cash, cash equivalents, restricted cash, and marketable securities as of December 31, 2023, were $237.0 million, compared to cash, cash equivalents, restricted cash, and marketable securities of $183.0 million as of September 30, 2023. The increase of $54 million was primarily related to the proceeds from the Roche collaboration and registered direct offering in Q4 2023. The Company expects its cash and cash equivalents, including proceeds from the Roche collaboration, to be sufficient to fund planned operations and capital expenditures into the first half of 2026.

06:35 EDT Restaurant Brands CFO Matt Dunnigan to depart, Sami Siddiqui to succeed - Josh Kobza, CEO of Restaurant Brands announced leadership team changes. Sami Siddiqui has been appointed CFO, succeeding Matt Dunnigan who is leaving the company. Jeff Klein has been appointed as President of Popeyes US and Canada, succeeding Siddiqui who has led the brand for nearly four years. Thiago Santelmo has been appointed president of International. Santelmo succeeds David Shear, who will remain with the company for a year as an advisor and assist in the transition. Today's leadership changes are effective immediately and a new president of EMEA and chief marketing officer for Popeyes will be named at a later date.

06:18 EDT AstraZeneca to acquire Amolyt Pharma for up to $1.05B - AstraZeneca announced that it has entered into a definitive agreement to acquire Amolyt Pharma, a clinical-stage biotechnology company focused on developing novel treatments for rare endocrine diseases. "The proposed acquisition will bolster the Alexion, AstraZeneca Rare Disease late-stage pipeline and expand on its bone metabolism franchise with the notable addition of eneboparatide, or AZP-3601, a Phase III investigational therapeutic peptide with a novel mechanism of action designed to meet key therapeutic goals for hypoparathyroidism. Additionally, Alexion is looking forward to welcoming talent from Amolyt Pharma," the company stated. Under the terms of the agreement, AstraZeneca will acquire all of Amolyt Pharma's outstanding shares for a total consideration of up to $1.05B, on a cash and debt free basis. This includes $800M upfront at deal closing, plus the right for Amolyt Pharma's shareholders to receive an additional contingent payment of $250M payable upon achievement of a specified regulatory milestone. Subject to the satisfaction of customary closing conditions in the acquisition agreement, including regulatory clearances, the transaction is expected to close by the end of the third quarter of 2024.

06:15 EDT First Wave BioPharma completes business combination with ImmunogenX - First Wave BioPharma has acquired ImmunogenX in an all-stock transaction with the combined company focused on advancing a GI pipeline comprised of multiple, late-stage clinical assets, including latiglutenase, a potentially first-in-class, near Phase 3-ready, targeted, oral biotherapeutic for celiac disease. James Sapirstein will continue to serve as Chairman and CEO of First Wave BioPharma with Jack Syage, previously the CEO and Co-Founder of ImmunogenX, assuming the role of President and COO of First Wave BioPharma. Syage and Chaitan Khosla will also join the board of directors of First Wave BioPharma. First Wave BioPharma intends to license the commercial rights to latiglutenase in the U.S. and Canada to a global pharmaceutical company which will commercialize latiglutenase following receipt of marketing approval. First Wave BioPharma will also seek to secure financing commitments to fund the ongoing development of latiglutenase. Latiglutenase, an oral biotherapeutic, has demonstrated effectiveness in reducing intestinal damage and alleviating symptoms of celiac disease in two Phase 2 trials involving approximately 200 patients. The Phase 3 clinical plan for latiglutenase has been reviewed by the FDA and the trials are anticipated to begin in early 2025. Upon closing of the acquisition, the company issued 365,162 shares of its common stock to the shareholders of ImmunogenX equal to 19.02% of its currently issued and outstanding common stock and 11,777.418 shares of its newly issued Series G Convertible Preferred Stock representing on a fully diluted basis 81.9% for ImmunogenX and 18.1% for First Wave Biopharma with a combined fully diluted equity value of $104M.

06:10 EDT PSQ Holdings acquires Credova Holdings - PSQ Holdings and Credova Holdings, a point-of-sale financing platform providing Buy Now Pay Later solutions catered to the shooting sports and firearms industries, entered into and consummated transactions that are the subject of an agreement and plan of merger dated as of March 13, including the merger of Credova with and into a wholly-owned subsidiary of the company established to facilitate the transaction. PublicSquare exchanged approximately 2.9 million shares of newly-issued Company Class A common stock for all of the outstanding shares of Credova. Additionally, all of Credova's outstanding subordinated debt was canceled and either repaid or exchanged for newly-issued 10-year PublicSquare promissory notes, convertible into Company Class A common stock. Following the Merger, Credova is a wholly-owned subsidiary of the company. Credova management, including its CEO Dusty Wunderlich, have joined PublicSquare and will continue to run Credova's business as part of PublicSquare. Wunderlich is also expected to join PublicSquare's board of directors. Credova has financed over a quarter billion dollars in transactions since its inception in 2018, and its merchant and customer universe is additive to PublicSquare, with over 4,800 merchants onboarded to date and 2.8 million unique applicants to date. The acquisition is expected to be immediately accretive to the company, before any anticipated synergies, as Credova financials reflect estimated net revenues of $15.5M, adjusted EBITDA of $2.3M and Free Cash Flow of $1.6M during FY2023. Credova has exclusive partnerships with over 60% of the top online shooting sports retailers. The transaction was approved by the boards of directors of PublicSquare and Credova and by requisite stockholders of Credova. Jim Giudice, former Chief Legal Officer of Credova, will replace Stephen Moran as PublicSquare's General Counsel. The remainder of the company's management team is expected to remain unchanged and PublicSquare will continue to be headquartered in West Palm Beach, Florida.

06:06 EDT Futu Holdings announces new $500M share repurchase program - The company announced its $500M share repurchase program in March 2022, and by 2023 year-end, the expiration date, the company had repurchased an aggregate of 11 million ADSs with approximately US$365 million in open market transactions. In addition, the company's board of directors has authorized a new share repurchase program under which the company may repurchase up to $500M worth of its ADSs, until December 31, 2025. The company plans to fund the repurchases from its existing cash balance.

05:58 EDT TE Connectivity to change place of incorporation to Ireland - The board of directors of TE Connectivity has unanimously approved a proposed change of the company's place of incorporation from Switzerland to Ireland. Shareholders will be asked to vote in favor of the proposal at a special general meeting of shareholders in Zurich, Switzerland. If approved, TE expects to implement the change in 2024. TE Connectivity does not anticipate any material change in its operations or financial results as a result of the change of domicile. The company will continue to be registered with the U.S. Securities and Exchange Commission, or SEC, and will be subject to the same SEC reporting requirements. The company's common shares will continue to trade on the NYSE under the symbol TEL. Switzerland will continue to serve as a TE leadership hub for strategic and operational functions.

05:52 EDT Nextracker, Orrcon Steel to deliver sovereign capability in Australia - Nextracker and Orrcon Steel, an Australian manufacturer of tube and pipe, and distributor of steel products and wholly owned business of BlueScope Steel, announced an agreement to manufacture and deliver Australian made critical components for Nextracker's smart solar tracker used on distributed generation and utility-scale solar farms. The first project scheduled to receive delivery of Australian made steel components from the facility is Acciona Energia's 480MWp Aldoga Solar Farm to be built near Gladstone. Critical steel components will be produced from BlueScope's steel coil at Orrcon Steel's Salisbury Tube mill in Brisbane and finished at its Northgate site by Baojia, Nextracker's global manufacturing partner for delivery to engineering procurement contractors. The new manufacturing facility was officially opened by Queensland Minister for Energy and Clean Economy Jobs.

05:38 EDT Fossil announces strategic review of current business model, capital structure - Fossil on Wednesday announced a strategic review of its current business model and capital structure. This includes efforts to optimize its business model through additional changes to its operations, as well as further structural cost reductions, which are under consideration. The company anticipates this effort will expand on its current TAG Plan and could include additional debt and equity financing options, including monetization of various assets to strengthen its balance sheet. The company has retained Evercore to act as its financial advisor. The company remains on track with its TAG Plan, which was announced in March 2023 and is designed to reduce operating expenses, improve operating margins and advance the company's commitment to profitable growth. The TAG Plan generated annualized operating income benefits of approximately $125M in 2023 and is expected to generate additional annualized operating income benefits of at least $100M in 2024. Restructuring costs associated with the TAG Plan are estimated to be $35M in fiscal year 2024 compared to $49M in fiscal year 2023.

05:33 EDT AirNet Technology regains compliance with Nasdaq - AirNet Technology announced that it received a notification letter from the Listing Qualifications Department of Nasdaq on March 13, indicating that the company has regained compliance with the minimum bid price requirement set forth in Rule 5550(a)(2) of the Nasdaq Listing Rules.

05:21 EDT Aurora Mobile enters strategic partnership with PERAC Eduverse - Aurora Mobile announced that it has entered into a strategic partnership with PERAC Eduverse, a subsidiary platform of Avantis Education, a teaching and learning company in the UK. Aurora Mobile will use its AI bot creation platform, GPTBots, to help PERAC Eduverse develop the ChatGPT AI series of courses for primary and secondary school students in Hong Kong, further promoting the development of AI STEAM by cultivating students' interest in AI. To achieve this goal, PERAC Eduverse has developed a series of interactive teaching and learning scenarios using GPTBots, including "Guangdong-Hong Kong-Macao Greater Bay Area Cultural City Planner", "Entrepreneurial Creative Thinking", "I Want to Be a Director" and "Greater Bay Area Career Exploration Planning". In these scenarios, students can use AI chatbots to generate content, sounds, and images to express their creative ideas. This collaboration between Aurora Mobile and PERAC Eduverse will also equip students with the tools and knowledge necessary to deeply understand the AI-driven world, helping them to succeed in future challenges and opportunities. This collaboration represents an effort to leverage AI technology for educational innovation, and both parties will continue to explore additional opportunities in the future.

05:08 EDT Lithium Americas receives $2.26B Thacker Pass project commitment from DOE - Lithium Americas (LAC) provided a construction plan update for its Thacker Pass lithium project located in Humboldt County, Nevada. Lithium Americas has received a conditional commitment from the U.S. Department of Energy, or DOE, for a $2.26B loan under the Advanced Technology Vehicles Manufacturing, or ATVM, Loan Program for financing the construction of the processing facilities at Thacker Pass, targeting to produce an initial 40,000 tons per year of battery grade lithium carbonate. The expected loan plus General Motors (GM) strategic investment are expected to provide the vast majority of the capital necessary to fund Phase 1. Site preparation for major earthworks has been completed, including all site clearing, commissioning a water supply system, site access improvements and site infrastructure. The company is currently focused on advancing detailed engineering, procurement and execution planning for the construction of Thacker Pass Phase 1. Detailed engineering is approximately 30% design complete to date, and the company plans to continue to increase the level of detailed engineering in advance of issuing full notice to proceed, or FNTP, which is expected in the second half of 2024. The company leased a parcel of land in the nearby City of Winnemucca for a transloading terminal to be used during operations, providing direct access to the mainline railroad and an interstate highway. The company and its engineering, procurement and construction management contractor, Bechtel, entered into a National Construction Agreement with North America's Building Trades Union for construction of Thacker Pass. Estimated total capital cost for Phase 1 construction has been revised to $2.93B to reflect updated quantities and execution planning tied to increased engineering progress, use of union labor through a PLA for construction of Thacker Pass, development of an all-inclusive housing facility for construction workers, updated equipment pricing and a larger project contingency. During the year ended December 31, 2023, approximately $194M was spent on Thacker Pass. The company expects capital expenditures to be significantly lower in the first half of 2024 as the focus turns from early works to advancing detailed engineering and project planning ahead of FNTP. Mechanical completion of Thacker Pass Phase 1 is targeted for 2027 following a three-year construction period. Major construction is expected to commence in the second half of 2024 following the anticipated closing of the DOE Loan and issuance of FNTP. In light of current market conditions and to preserve liquidity, the company has reduced project capital expenditures to minimal levels until closing of the DOE Loan and issuance of FNTP, which are expected in the second half of the year. In addition, the company has taken actions to reduce its general and administrative and operating expense budget for 2024 by more than 25%.